Schoedel KA[au] - Search Results

Year	Number of Results
2001	1
2003	2
2004	1
2007	2
2008	1
2010	3
2011	4
2012	5
2013	1
2014	2
2015	2
2016	4
2017	3
2018	4
2019	2
2020	1
2021	1
2022	2
2024	0

1

Human abuse liability evaluation of CNS stimulant drugs.

Romach MK, Schoedel KA, Sellers EM. Romach MK, et al. Among authors: schoedel ka. Neuropharmacology. 2014 Dec;87:81-90. doi: 10.1016/j.neuropharm.2014.04.014. Epub 2014 Apr 30. Neuropharmacology. 2014. PMID: 24793872 Review.

2

Evaluating the abuse potential of opioids and abuse-deterrent -opioid formulations: A review of clinical study methodology.

Setnik B, Schoedel KA, Levy-Cooperman N, Shram M, Pixton GC, Roland CL. Setnik B, et al. Among authors: schoedel ka. J Opioid Manag. 2017 Nov/Dec;13(6):485-523. doi: 10.5055/jom.2017.0412. J Opioid Manag. 2017. PMID: 29308594 Review.

3

Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect.

Schoedel KA, Morrow SA, Sellers EM. Schoedel KA, et al. Neuropsychiatr Dis Treat. 2014 Jun 26;10:1161-74. doi: 10.2147/NDT.S30713. eCollection 2014. Neuropsychiatr Dis Treat. 2014. PMID: 25061302 Free PMC article. Review.

4

Update on tamper-resistant drug formulations.

Romach MK, Schoedel KA, Sellers EM. Romach MK, et al. Among authors: schoedel ka. Drug Alcohol Depend. 2013 Jun 1;130(1-3):13-23. doi: 10.1016/j.drugalcdep.2012.12.028. Epub 2013 Feb 13. Drug Alcohol Depend. 2013. PMID: 23415386 Review.

5

Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data.

Schoedel KA, Kolly C, Gardin A, Neelakantham S, Shakeri-Nejad K. Schoedel KA, et al. Psychopharmacology (Berl). 2022 Jan;239(1):1-13. doi: 10.1007/s00213-021-06011-6. Epub 2021 Nov 13. Psychopharmacology (Berl). 2022. PMID: 34773483 Free PMC article. Review.

6

Assessing abuse liability during drug development: changing standards and expectations.

Schoedel KA, Sellers EM. Schoedel KA, et al. Clin Pharmacol Ther. 2008 Apr;83(4):622-6. doi: 10.1038/sj.clpt.6100492. Epub 2008 Jan 23. Clin Pharmacol Ther. 2008. PMID: 18212799 Review.

7

Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications.

Schoedel KA, Tyndale RF. Schoedel KA, et al. Biochim Biophys Acta. 2003 Feb 17;1619(3):283-90. doi: 10.1016/s0304-4165(02)00487-7. Biochim Biophys Acta. 2003. PMID: 12573488 Review.

8

Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research.

Schoedel KA, Harrison SJ. Schoedel KA, et al. Curr Pharm Des. 2012;18(32):5008-14. doi: 10.2174/138161212802884708. Curr Pharm Des. 2012. PMID: 22716155 Review.

9

Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.

Ufer M, Kelsh D, Schoedel KA, Dingemanse J. Ufer M, et al. Among authors: schoedel ka. Sleep. 2022 Mar 14;45(3):zsab224. doi: 10.1093/sleep/zsab224. Sleep. 2022. PMID: 34480579 Clinical Trial.

10

Pharmacokinetic and Pharmacodynamic Correlations From 2 Studies Evaluating Abuse Potential of Hydrocodone Extended-Release Tablets.

Schoedel KA, Gillespie M, Levy-Cooperman N, Shram MJ, Rabinovich-Guilatt L. Schoedel KA, et al. Clin Pharmacol Drug Dev. 2019 Jan;8(1):32-39. doi: 10.1002/cpdd.468. Epub 2018 May 3. Clin Pharmacol Drug Dev. 2019. PMID: 29723441 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

37 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year